← Home
Eli Lilly and Company
-7.79%
Pharma / Pharma
📢 Press Releases
| Date | Press release |
|---|---|
| 2025-05-29 17:00:00 | Lilly Announces Details Of Presentations At American Diabetes Association’s (ada) 85th Scientific Sessions Indianapolis , may 29, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (zepbound and mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the american diabetes association’s (ada) 85th scientific sessions taking place june 20-23 in chicago. lilly will also host an investor event to highlight the company’s cardiometabolic health portfolio and discuss key presentations from the ada scientific sessions. |
| 2025-05-27 10:00:00 | Lilly To Expand Its Pain Pipeline With Acquisition Of Siteone Therapeutics Transaction will augment lilly’s efforts to advance non-opioid medicines for pain management indianapolis , may 27, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) and siteone therapeutics, inc. (’siteone’), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for lilly to acquire siteone. the transaction includes stc-004, a phase 2 ready nav1.8 inhibitor being studied for the treatment of pain. |
| 2025-05-11 18:01:00 | Zepbound (tirzepatide) Showed Superior Weight Loss Over Wegovy (semaglutide) In Complete Surmount-5 Results Published In The New England Journal Of Medicine Participants achieved an average weight loss of 20.2% with zepbound vs. 13.7% with wegovy in key secondary endpoints, zepbound was superior to wegovy across all weight reduction targets and waist circumference reduction indianapolis , may 11, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) today announced detailed results from surmount-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of zepbound (tirzepatide), a dual gip and glp-1 receptor agonist, compared to wegovy (semaglutide), a mono glp-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. |
| 2025-05-09 08:00:00 | Lilly Plans To Expand Purdue University Collaboration With Up To A $250 Million Investment To Accelerate Pharmaceutical Innovation Indianapolis and west lafayette, ind. , may 9, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) and purdue university announced today a significant expansion of their long-standing alliance, with lilly’s planned investment of up to $250 million in the collaboration over the next eight years. |
| 2025-05-08 06:45:00 | Lilly Announces Transitions In Executive Leadership Indianapolis , may 8, 2025 /prnewswire/ -- eli lilly and company (nyse: lly) today announced executive leadership transitions that will further enhance the company’s ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide. lilly has experienced significant growth over the past several years, particularly in the u.s. and cardiometabolic health businesses. |
| 2025-05-07 07:30:00 |
|
| 2025-05-06 07:30:00 |
|
| 2025-05-05 12:47:00 |
|
| 2025-05-05 07:25:00 |
|
| 2025-05-02 13:40:00 |
|
| 2025-05-02 10:00:00 |
|
| 2025-05-01 06:45:00 |
|
| 2025-04-29 10:07:00 |
|
| 2025-04-17 10:00:00 |
|
| 2025-04-17 09:00:00 |
|
📰 Browse additional press releases for Eli Lilly and Company!
Sign up for free or log in🎁 Free download! "The Checklist Value Investor — A Smarter Way to Pick Stocks"